Wall Street analysts expect that Jounce Therapeutics Inc (NASDAQ:JNCE) will announce $99.97 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Jounce Therapeutics’ earnings, with the lowest sales estimate coming in at $85.00 million and the highest estimate coming in at $118.00 million. Jounce Therapeutics posted sales of $14.53 million during the same quarter last year, which suggests a positive year-over-year growth rate of 588%. The company is scheduled to report its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Jounce Therapeutics will report full-year sales of $134.24 million for the current financial year, with estimates ranging from $53.00 million to $176.43 million. For the next year, analysts forecast that the business will report sales of $84.00 million, with estimates ranging from $50.00 million to $118.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $17.45 million for the quarter, compared to analysts’ expectations of $17.09 million. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%.

Separately, JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a research note on Sunday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $10.00.

NASDAQ JNCE traded up $0.02 during trading on Monday, reaching $3.96. The company’s stock had a trading volume of 178,500 shares, compared to its average volume of 327,194. The stock has a market capitalization of $135.55 million, a PE ratio of -4.71 and a beta of 3.44. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.03 and a quick ratio of 2.03. The firm has a fifty day moving average of $4.43 and a 200 day moving average of $5.03. Jounce Therapeutics has a one year low of $2.66 and a one year high of $8.58.

A number of hedge funds and other institutional investors have recently made changes to their positions in JNCE. Assenagon Asset Management S.A. increased its stake in Jounce Therapeutics by 479.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 278,100 shares of the company’s stock worth $1,724,000 after acquiring an additional 230,109 shares during the last quarter. Vanguard Group Inc. increased its stake in Jounce Therapeutics by 30.8% in the 2nd quarter. Vanguard Group Inc. now owns 800,150 shares of the company’s stock worth $3,961,000 after acquiring an additional 188,540 shares during the last quarter. Acadian Asset Management LLC increased its stake in Jounce Therapeutics by 108.3% in the 1st quarter. Acadian Asset Management LLC now owns 291,533 shares of the company’s stock worth $1,807,000 after acquiring an additional 151,576 shares during the last quarter. Strs Ohio bought a new position in shares of Jounce Therapeutics during the 2nd quarter valued at about $470,000. Finally, Dupont Capital Management Corp bought a new position in shares of Jounce Therapeutics during the 2nd quarter valued at about $321,000. Institutional investors and hedge funds own 73.54% of the company’s stock.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.